Results 21 to 30 of about 76,979 (321)
Clinical Infectious Diseases, 2020 Background Pneumococcal conjugate vaccines (PCVs) have significantly decreased pneumococcal disease worldwide; however, expanding serotype coverage may further reduce disease burden.
D. Hurley +10 more
semanticscholar +1 more source
Nature Communications, 2020 There are concerns that pneumococcal conjugate vaccines (PCVs) in sub-Saharan Africa sub-optimally interrupt Streptococcus pneumoniae vaccine-serotype (VT) carriage and transmission.
T. Swarthout +15 more
semanticscholar +1 more source
Co-evolution of Vaccination Behavior and Perceived Vaccination Risk can lead to a Stag-Hunt like Game [PDF]
, 2022 Voluntary vaccination is effective to prevent infectious diseases from spreading. Both vaccination behavior and cognition of the vaccination risk play important roles in individual vaccination decision making. However, it is not clear how the co-evolution of the two shapes the population-wide vaccination behavior.
arxiv +1 more source
Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report
Journal of Medical Case Reports, 2017 Background The United States Advisory Committee on Immunization Practices recommends administration of the 13-valent pneumococcal conjugate vaccine in series with the 23-valent pneumococcal polysaccharide vaccine for prevention of pneumonia in the ...
Pierre Tawfik +2 more
doaj +1 more source
Vaccine hesitancy and receipt of mandatory and optional pediatric vaccines in Shanghai, China
Human Vaccines & Immunotherapeutics, 2022 Given increased global concern about vaccine hesitancy, this study estimates coverage of mandatory vs non-mandatory vaccines in children, and assesses whether vaccine hesitancy among young parents relates to their childʻs eventual vaccination status in ...
Mengdi Ji +3 more
doaj +1 more source
Accurate Measures of Vaccination and Concerns of Vaccine Holdouts from Web Search Logs [PDF]
, 2023 To design effective vaccine policies, policymakers need detailed data about who has been vaccinated, who is holding out, and why. However, existing data in the US are insufficient: reported vaccination rates are often delayed or missing, and surveys of vaccine hesitancy are limited by high-level questions and self-report biases. Here, we show how large-
arxiv +1 more source
The Pediatric Infectious Disease Journal, 2020 Supplemental Digital Content is available in the text. Background: Pneumococcal disease remains a public health priority worldwide. This phase 2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and immunogenicity of 2 clinical lots ...
H. Platt +14 more
semanticscholar +1 more source
PLoS ONE, 2019 BackgroundDespite the widespread implementation of the pneumococcal conjugate vaccine, Streptococcus pneumoniae remains the leading cause of severe pneumonia associated with mortality among children less than 5 years of age worldwide, with the highest ...
James Samwel Ngocho +6 more
doaj +1 more source
Emerging Infectious Diseases, 2015 Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1,
Mirjam J. Knol +6 more
doaj +1 more source
MMWR. Morbidity and mortality weekly report, 2019 Two pneumococcal vaccines are currently licensed for use in adults in the United States: a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Pfizer, Inc.]) and a 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co.
Almea M Matanock +5 more
semanticscholar +1 more source